Literature DB >> 11917160

Mouse models of Alzheimer's disease: a quest for plaques and tangles.

James A Richardson1, Dennis K Burns.   

Abstract

Many genetically altered mice have been designed to help understand the role of specific gene mutations in the pathogenesis of Alzheimer's disease (AD) based on the realization that specific mutations in the genes for amyloid precursor protein--the presenilins and tau--are associated with early-onset familial AD or, in the case of tau mutations, other neurodegenerative diseases with neurofibrillary tangles. However, attempts to reproduce the neuropathology of AD in the mouse have been frustrating. Transgenic designs emphasizing amyloid precursor protein produced mice that develop amyloid plaques, but neurodegeneration and neurofibrillary tangles failed to form. Strategies emphasizing tau resulted in increased phosphorylation of tau and tangle formation, although amyloid plaques were absent. Nevertheless, crossing transgenic animals expressing mutated tau and amyloid precursor protein has produced a mouse that closely recapitulates the neuropathology of AD. A review of the various murine models, their role in understanding the pathogenesis of AD and their use in testing therapeutic regimens, is provided.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11917160     DOI: 10.1093/ilar.43.2.89

Source DB:  PubMed          Journal:  ILAR J        ISSN: 1084-2020


  16 in total

Review 1.  Synaptic plasticity in animal models of early Alzheimer's disease.

Authors:  Michael J Rowan; Igor Klyubin; William K Cullen; Roger Anwyl
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2003-04-29       Impact factor: 6.237

2.  Interactions of Npc1 and amyloid accumulation/deposition in the APP/PS1 mouse model of Alzheimer's.

Authors:  Ivan A Borbon; Robert P Erickson
Journal:  J Appl Genet       Date:  2010-12-18       Impact factor: 3.240

Review 3.  Gene therapy for misfolding protein diseases of the central nervous system.

Authors:  Waldy San Sebastian; Lluis Samaranch; Adrian P Kells; John Forsayeth; Krystof S Bankiewicz
Journal:  Neurotherapeutics       Date:  2013-07       Impact factor: 7.620

4.  Genetic ablation of luteinizing hormone receptor improves the amyloid pathology in a mouse model of Alzheimer disease.

Authors:  Jing Lin; Xian Li; Fangping Yuan; Ling Lin; Christine L Cook; Ch V Rao; Zhenmin Lei
Journal:  J Neuropathol Exp Neurol       Date:  2010-03       Impact factor: 3.685

Review 5.  Calcium-regulated signaling pathways: role in amyloid beta-induced synaptic dysfunction.

Authors:  Cui-Wei Xie
Journal:  Neuromolecular Med       Date:  2004       Impact factor: 3.843

6.  Toll-interacting protein deficiency promotes neurodegeneration via impeding autophagy completion in high-fat diet-fed ApoE-/- mouse model.

Authors:  Keqiang Chen; Ruoxi Yuan; Shuo Geng; Yao Zhang; Taojing Ran; Elizabeth Kowalski; Jingze Liu; Liwu Li
Journal:  Brain Behav Immun       Date:  2016-10-05       Impact factor: 7.217

Review 7.  Review of pathological hallmarks of schizophrenia: comparison of genetic models with patients and nongenetic models.

Authors:  Hanna Jaaro-Peled; Yavuz Ayhan; Mikhail V Pletnikov; Akira Sawa
Journal:  Schizophr Bull       Date:  2009-11-10       Impact factor: 9.306

Review 8.  Transgenic models of Alzheimer's disease: better utilization of existing models through viral transgenesis.

Authors:  Thomas L Platt; Valerie L Reeves; M Paul Murphy
Journal:  Biochim Biophys Acta       Date:  2013-04-22

9.  MRI and histological analysis of beta-amyloid plaques in both human Alzheimer's disease and APP/PS1 transgenic mice.

Authors:  Mark D Meadowcroft; James R Connor; Michael B Smith; Qing X Yang
Journal:  J Magn Reson Imaging       Date:  2009-05       Impact factor: 4.813

10.  Mutant amyloid precursor protein differentially alters adipose biology under obesogenic and non-obesogenic conditions.

Authors:  Linnea R Freeman; Le Zhang; Kalavathi Dasuri; Sun-Ok Fernandez-Kim; Annadora J Bruce-Keller; Jeffrey N Keller
Journal:  PLoS One       Date:  2012-08-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.